Allergies News and Research

Latest Allergies News and Research

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Teens involved in research studies prefer telephones over social media

If you think teenagers prefer social media over the telephone, you may want to think again, at least when it comes to teens involved in research studies.

12 Aug 2011

New technique can help develop HIV vaccines

Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week.

12 Aug 2011

Allergy & Asthma Specialists, P.C. adopts Aerocrine's FENO technology

Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine's FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis.

12 Aug 2011

Leading dental and pharmacy organizations to raise awareness on xerostomia

Leading dental and pharmacy organizations are teaming up to promote oral health and raise public awareness of dry mouth, a side effect commonly caused by taking prescription and over-the-counter medications.

12 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

Researchers discover key reason why pyrazinamide shortens duration of TB therapy

Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood.

12 Aug 2011

Mercury and autism link strengthened

The researchers from Swinburne University in Melbourne surveyed 522 Australian survivors of Pink disease - a form of mercury poisoning common in the early 20th century - found one in 25 of their 398 grandchildren aged six to 12 had an autism spectrum disorder.

10 Aug 2011

A diet of flaxseed shows protective effects against radiation in mice

Flax has been part of human history for well over 30,000 years, used for weaving cloth, feeding people and animals, and even making paint. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania have discovered that it might have a new use for the 21st century: protecting healthy tissues and organs from the harmful effects of radiation.

10 Aug 2011

Researchers identify molecular pathway behind inflammation, mucus production in asthma

Researchers at the University of Pittsburgh School of Medicine have identified a molecular pathway that helps explain how an enzyme elevated in asthma patients can lead to increased mucus production and inflammation that is characteristic of the lung condition.

9 Aug 2011

Study finds key influential factors linked with risk of allergies in babies

Prenatal pet exposure, a mother's delivery mode and race are influential factors in a child's risk of developing allergies by age 2, according to a Henry Ford Hospital study.

9 Aug 2011

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person's central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.

8 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Scientist urges federal officials to decide on genetically engineered salmon for consumption

A Purdue University scientist is urging federal officials to decide whether genetically engineered salmon would be allowed for U.S. consumption and arguing that not doing so may set back scientific efforts to increase food production.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

First anti-venom for scorpion bites approved by FDA

The U.S. Food and Drug Administration (FDA) has approved a Mexican-made drug that is the first specific treatment for stings by the most common type of scorpion in the United States. The new preparation called Anascorp is found to have few allergic reactions and was approved after a series of clinical trials by the University of Arizona.

5 Aug 2011

FDA approves first scorpion antivenom

The U.S. Food and Drug Administration today approved Anascorp-, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.

5 Aug 2011

Study: Poorly controlled asthma doubles healthcare costs linked with disease

Poorly controlled asthma more than doubles healthcare costs associated with the disease and threatens educational achievement through a dramatic increase in school absence, according to researchers at National Jewish Health.

5 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

Tips to minimize risk of bug bites and related illnesses

While the image of a bug crawling on your arm or a creepy crawler snuggling up in your bed is enough to make you flinch, most bug bites are harmless and disappear on their own in a matter of days. Other insects, however, can spread disease and cause severe reactions that require medical attention.

4 Aug 2011